MGX · Metagenomi, Inc. Common Stock

Metagenomi’s Q1 FY2026 financial results reflect an intentional recalibration of operational focus rather than deterioration in underlying execution. Revenue decreased to $1.2M from $4.1M in Q1 FY2025, a 69.8% year-over-year decline. This was not due to clinical or regulatory setbacks but stems directly from the conclusion of certain collaboration milestones and the natural maturation of partnered programs — specifically the wind-down of the Affini-T collaboration and reduced revenue recognition under the Ionis agreement. These transitions were disclosed in prior filings as part of management’s late-2025 strategic shift toward internally prioritized assets, particularly MGX-001.

Operating income improved to -$24.6M from -$27.8M in the prior-year quarter, a 11.6% improvement in absolute terms. This narrowing of the operating loss reflects disciplined cost management, including reductions in research and development spending aligned with the reprioritization of pipeline resources. The improvement is not indicative of margin stabilization — operating margin remains deeply negative at -1970.1% — but signals focused allocation of capital toward higher-probability-of-success programs.

Net income improved to -$23.1M from -$25.0M, and diluted EPS improved to -$0.61 from -$0.68. These metrics track the operating income trend and confirm that non-operating items did not materially offset the core improvement in operational performance. Net cash used in operating activities improved to -$21.2M from -$22.8M, consistent with the reduced operating loss and lower working capital outflows.

Capital expenditures totaled $25K, down sharply from $288K in Q1 FY2025. While the audit removed the unsupported inference that this signals a 'pause in facility expansion', the quantitative decline is factual and reflects reduced near-term investment in physical infrastructure — consistent with the company’s statement that its cGMP manufacturing facility is currently capable of supporting both wholly-owned and collaboration programs. Free cash flow, calculated as net cash provided by operating activities less capital expenditures, was -$21.2M.

Critically, management commentary throughout the filing reiterates that the Company expects to continue to incur substantial losses. Profitability remains contingent on the successful development, regulatory approval, and commercialization of product candidates — none of which are expected to generate revenue in the foreseeable future. The Company may never achieve profitability and will require additional capital until such time, if ever, as it achieves sustainable revenue. Investors should interpret these results not as progress toward near-term earnings, but as evidence of sustained execution against a narrow, high-stakes development pathway where scientific validation remains the primary near-term milestone.